Pliant Therapeutics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Pliant Therapeutics sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).

7 total trials 1 currently recruiting 4 completed early-phase tilt upper quartile by trial count

Pliant Therapeutics: 7 sponsored US clinical trials, 1 recruiting.

Pliant Therapeutics sponsors 7 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 4 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Idiopathic Pulmonary Fibrosis, with 1 trials.

Upper-quartile sponsor footprint

Pliant Therapeutics sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

7 total, page 1 of 1

RECRUITING Phase 1

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

NCT06270706
TERMINATED Phase 2

Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

NCT06097260
COMPLETED Phase 2

Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809)

NCT05621252
TERMINATED Phase 2

Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19

NCT04565249
COMPLETED Phase 2

Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)

NCT04480840
COMPLETED Phase 2

Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis

NCT04396756
COMPLETED Phase 2

Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/

NCT04072315

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 6

Therapeutic Areas

Idiopathic Pulmonary Fibrosis 1

What is open in the Pliant Therapeutics pipeline

1 recruiting of 7 indexed (14% open); 4 completed (57%).

Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).

Top condition: Idiopathic Pulmonary Fibrosis (1 trial), 0 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Pliant Therapeutics: open-pipeline peers nationwide

Peers matched on 7 registered trials and 14% open enrollment, not the therapeutic-area sidebar.

Pliant Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 01020304050 0%10%20%30%40% Total trials Recruiting share Pliant Therapeutics3M4Life Research89bioAbbott Diagnostics DivisionAcademic and Community Cancer Research UnitedAdaptive BiotechnologiesAgelessRxAlaska Blind Child Discovery
Pliant Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Pliant Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 7 trials (± recruiting share)

Sponsors near 14% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Pliant Therapeutics page

7 registered trials is a research-attention snapshot, not an endorsement of Pliant Therapeutics or any single study.

  • 1 of Pliant Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Idiopathic Pulmonary Fibrosis is the condition Pliant Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Idiopathic Pulmonary Fibrosis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Pliant Therapeutics pipeline card: 7 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.